Mr. Huitt Tracey reports

NERVGEN PHARMA GRANTS STOCK OPTIONS

Nervgen Pharma Corp. has granted 400,000 incentive stock options to directors of the company, exercisable at a price of $1.61 per share for a period of five years and that vest equally every three months over a one-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the company's stock option plan.

About Nervgen Pharma Corp.

Nervgen is a clinical-stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indications are spinal cord injury, Alzheimer's disease and multiple sclerosis.